Geriatric Obesity: Evaluating the Evidence for the Use of Flavonoids to Promote Weight Loss

Journal of Nutrition in Gerontology and Geriatrics

Volumn 31, Issue 3, 2012, Pages 269-289

  Hurt, Ryan T ^a,b   Wilson, Ted ^c  

^a MAYO CLINIC   (United States)

^b University of Louisville School of Medicine   (United States)

^c WINONA STATE UNIVERSITY   (United States)

Author keywords

EGCG; flavonoids; green tea; obesity; quercetin; soy isoflavone

Indexed keywords

CATECHIN; FLAVONOID; ISOFLAVONE DERIVATIVE; PLANT EXTRACT; QUERCETIN;

AGED; ARTICLE; DIET SUPPLEMENTATION; DRUG EFFECT; HUMAN; OBESITY; PHYTOTHERAPY; UNITED STATES; WEIGHT REDUCTION;

AGED; CATECHIN; DIETARY SUPPLEMENTS; FLAVONOIDS; HUMANS; ISOFLAVONES; OBESITY; PHYTOTHERAPY; PLANT EXTRACTS; QUERCETIN; UNITED STATES; WEIGHT LOSS;

EID: 84865095798     PISSN: 21551197     EISSN: 21551200     Source Type: Journal    
DOI: 10.1080/21551197.2012.698222     Document Type: Article

References (96)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012; 307 (5): 491-7.
2. Finkelstein EA, Ruhm CJ, Kosa KM. Economic causes and consequences of obesity. Annu Rev Public Health. 2005; 26: 239-57.
3. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007; 132 (6): 2087-102.
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348 (17): 1625-38.
5. Hurt RT, Frazier TH, McClave SA, Cave MC. Pharmaconutrition for the obese, critically ill patient. JPEN. 2011; 35 (5 SUPPL.): 60S-72S.
6. Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, et al.Dietary supplement use in the United States, 2003-2006. J Nutr.2011; 141(2):261-6.
7. Lenz TL, Hamilton WR. Supplemental products used for weight loss. J Am Pharm Assoc. 2004; 44 (1): 59-67. quiz 8.
8. Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Burton SL, Wadden TA. Use of dietary supplements for weight loss in the United States: results of a national survey. Obesity (Silver Spring). 2008; 16 (4): 790-6.
9. Wilson T, Bauer BA. Advising consumers about dietary supplements: lessons from cranberry products. Journal Dietary SUPPL. 2009; 6 (4): 377-84.
10. Kuczmarski RJ, Flegal KM. Criteria for definition of overweight in transition: background and recommendations for the United States. Am J Clin Nutr. 2000; 72 (5): 1074-81.
11. Bales CW, Buhr G. Is obesity bad for older persons? A systematic review of the pros and cons of weight reduction in later life. J Am Med Dir Assoc. 2008; 9 (5): 302-12.
12. Han TS, Tajar A, Lean ME. Obesity and weight management in the elderly. British Medical Bulletin. 2011; 97: 169-96.
13. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006; 355 (8): 763-78.
14. Hurt RT, Kulisek C, Buchanan LA, McClave SA. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol (NY). 2010; 6 (12): 780-92.
15. Pischon T, Nothlings U, Boeing H. Obesity and cancer. Proc Nutr Soc. 2008; 67 (2): 128-45.
16. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373 (9669): 1083-96.
17. Kiraly L, Hurt RT, Van Way CW, 3rd. The outcomes of obese patients in critical care. JPEN. 2011; 35 (5 SUPPL.): 29S-35S.
18. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiology. 2004; 43 (8): 1439-44.
19. Volpato S, Zuliani G, Guralnik JM, Palmieri E, Fellin R. The inverse association between age and cholesterol level among older patients: the role of poor health status. Gerontology. 2001; 47 (1): 36-45.
20. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney International. 2002; 61 (5): 1887-93.
21. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005; 81 (3): 543-54.
22. Lainscak M, von Haehling S, Doehner W, Sarc I, Jeric T, et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle. 2011; 2 (2): 81-6.
23. Lee CG, Boyko EJ, Nielson CM, Stefanick ML, Bauer DC, et al. Mortality risk in older men associated with changes in weight, lean mass, and fat mass. J Am Geriatr Soc. 2011; 59 (2): 233-40.
24. Grabowski DC, Campbell CM, Ellis JE. Obesity and mortality in elderly nursing home residents. J Gerontol A Biol Sci Med Sci.2005; 60(9):1184-9.
25. Grabowski DC, Ellis JE. High body mass index does not predict mortality in older people: analysis of the Longitudinal Study of Aging. J Am Geriatr Soc. 2001; 49 (7): 968-79.
26. Waters DL, Baumgartner RN. Sarcopenia and obesity. Clin Geriatr Med. 2011; 27 (3): 401-21.
27. Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS. Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab. 2000; 85 (3): 977-82.
28. Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity (Silver Spring). 2009; 17 SUPPL. 1.: S1-70, v.
29. Egert S, Rimbach G. Which sources of flavonoids: complex diets or dietary supplements? Adv Nutr. 2011; 2 (1): 8-14.
30. Hursel R, Viechtbauer W, Westerterp-Plantenga MS. The effects of green tea on weight loss and weight maintenance: a meta-analysis. Int J Obes (Lond). 2009; 33 (9): 956-61.
31. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006; 296 (10): 1255-65.
32. Carlson JR, Bauer BA, Vincent A, Limburg PJ, Wilson T. Reading the tea leaves: anticarcinogenic properties of (-)-epigallocatechin-3-gallate. Mayo Clinic proceedings. Mayo Clinic. 2007; 82 (6): 725-32.
33. Thavanesan N. The putative effects of green tea on body fat: an evaluation of the evidence and a review of the potential mechanisms. Br J Nutr. 2011; 106 (9): 1297-309.
34. Grove KA, Lambert JD. Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity. J Nutr. 2010; 140 (3): 446-53.
35. Chacko SM, Thambi PT, Kuttan R, Nishigaki I. Beneficial effects of green tea: a literature review. Chin Med. 2010; 5: 13.
36. Wedick NM, Pan A, Cassidy A, Rimm EB, Sampson L, et al. Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. Am J Clin Nutr. 2012; 95: 925-33.
37. Tsuneki H, Ishizuka M, Terasawa M, Wu JB, Sasaoka T, Kimura I. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol. 2004; 4: 18.
38. Wu LY, Juan CC, Hwang LS, Hsu YP, Ho PH, Ho LT. Green tea supplementation ameliorates insulin resistance and increases glucose transporter IV content in a fructose-fed rat model. Eur J Nutr. 2004; 43 (2): 116-24.
39. Yan J, Zhao Y, Suo S, Liu Y, Zhao B. Green tea catechins Ameliorates Adipose Insulin Resistance by Improving Oxidative Stress. Free Radic Biol Med. 2012; 52: 1648-57.
40. Hsu CH, Liao YL, Lin SC, Tsai TH, Huang CJ, Chou P. Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. Alternative Medicine Review. 2011; 16(2):157-63.
41. Kim JH, Kang MJ, Choi HN, Jeong SM, Lee YM, Kim JI. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr Res Pract. 2011; 5 (2): 107-11.
42. Youl E, Bardy G, Magous R, Cros G, Sejalon F, et al. Quercetin potentiates insulin secretion and protects INS-1 pancreatic beta-cells against oxidative damage via the ERK1/2 pathway. Br J Pharmacol. 2010; 161 (4): 799-814.
43. Llaneza P, Gonzalez C, Fernandez-Inarrea J, Alonso A, Diaz F, Perez-Lopez FR. Soy isoflavones improve insulin sensitivity without changing serum leptin among postmenopausal women. Climacteric: The Journal of the International Menopause Society. 2011; 23 December. doi:10.3109/13697137.2011.631062. [Epub ahead of print]
44. Mueller NT, Odegaard AO, Gross MD, Koh WP, Yu MC, et al. Soy intake and risk of type 2 diabetes mellitus in Chinese Singaporeans: soy intake and risk of type 2 diabetes. Eur J Nutr. 2011; 18 November. doi:10.1007/s00394-011-0276-2. [Epub ahead of print]
45. Furuyashiki T, Nagayasu H, Aoki Y, Bessho H, Hashimoto T, et al. Tea catechin suppresses adipocyte differentiation accompanied by down-regulation of PPARgamma2 and C/EBPalpha in 3T3-L1 cells. Biosci Biotechnol Biochem. 2004; 68 (11): 2353-9.
46. Wolfram S, Wang Y, Thielecke F. Anti-obesity effects of green tea: from bedside to bench. Mol Nutr Food Res. 2006; 50 (2): 176-87.
47. Lin JK, Lin-Shiau SY. Mechanisms of hypolipidemic and anti-obesity effects of tea and tea polyphenols. Mol Nutr Food Res. 2006; 50 (2): 211-7.
48. Yang L, Li XF, Gao L, Zhang YO, Cai GP. Suppressive effects of quercetin-3-O-(6"-Feruloyl)-beta-D-galactopyranoside on adipogenesis in 3T3-L1 preadipocytes through down-regulation of PPARgamma and C/EBPalpha expression. PTR. 2012; 26 (3): 438-44.
49. Shen P, Liu MH, Ng TY, Chan YH, Yong EL. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro. J Nutr. 2006; 136 (4): 899-905.
50. Harmon AW, Patel YM, Harp JB. Genistein inhibits CCAAT/enhancer-binding protein beta (C/EBPbeta) activity and 3T3-L1 adipogenesis by increasing C/EBP homologous protein expression. Biochem J. 2002; 367 (Pt 1): 203-8.
51. Kim HK, Nelson-Dooley C, Della-Fera MA, Yang JY, Zhang W, et al. Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. J Nutr. 2006; 136 (2): 409-14.
52. Orgaard A, Jensen L. The effects of soy isoflavones on obesity. Exp Biol Med (Maywood). 2008; 233 (9): 1066-80.
53. Jung CH, Cho I, Ahn J, Jeon TI, Ha TY. Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. Phytother Res. 2012; 23 March. doi:10.1002/ptr.4687. [Epub ahead of print]
54. Wolfram S, Raederstorff D, Wang Y, Teixeira SR, Elste V, Weber P. TEAVIGO (epigallocatechin gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass. Ann Nutr Metab.2005; 49(1):54-63.
55. Ashida H, Furuyashiki T, Nagayasu H, Bessho H, Sakakibara H, et al. Anti-obesity actions of green tea: possible involvements in modulation of the glucose uptake system and suppression of the adipogenesis-related transcription factors. Biofactors. 2004; 22 (1-4): 135-40.
56. Lee K. Transactivation of peroxisome proliferator-activated receptor alpha by green tea extracts. J Vet Sci. 2004; 5 (4): 325-30.
57. Park HJ, DiNatale DA, Chung MY, Park YK, Lee JY, et al. Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. J Nutr Biochem. 2011; 22 (4): 393-400.
58. Mezei O, Li Y, Mullen E, Ross-Viola JS, Shay NF. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and -independent mechanisms. Physiol Genomics. 2006; 26 (1): 8-14.
59. Borradaile NM, de Dreu LE, Wilcox LJ, Edwards JY, Huff MW. Soya phytoestrogens, genistein and daidzein, decrease apolipoprotein B secretion from HepG2 cells through multiple mechanisms. Biochem J. 2002; 366 (Pt 2): 531-9.
60. Mohamed Salih S, Nallasamy P, Muniyandi P, Periyasami V, Carani Venkatraman A. Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance. J Diabetes. 2009; 1 (4): 278-87.
61. Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Muller MJ. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr. 2010; 140 (2): 278-84.
62. Knab AM, Shanely RA, Henson DA, Jin F, Heinz SA, et al. Influence of quercetin supplementation on disease risk factors in community-dwelling adults. J Am Diet Assoc. 2011; 111 (4): 542-9.
63. Talirevic E, Jelena S. Quercetin in the treatment of dyslipidemia. Medicinski Arhiv. 2012; 66 (2): 87-8.
64. Granado-Serrano AB, Martin MA, Bravo L, Goya L, Ramos S. Quercetin Attenuates TNF-Induced Inflammation in Hepatic Cells by Inhibiting the NF-kappaB Pathway. Nutr. Cancer. 2012; 64 (4): 588-98.
65. Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, et al. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract. 2008; 23 (1): 16-34.
66. Hurt RT, Frazier TH, Matheson PJ, Cave MC, Garrison RN, et al. Obesity and inflammation: should the principles of immunonutrition be applied to this disease process? Curr Gastroenterol Rep. 2007; 9 (4): 305-6.
67. Park HJ, Lee JY, Chung MY, Park YK, Bower AM, et al. Green tea extract suppresses NFkappaB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis. J Nutr. 2012; 142 (1): 57-63.
68. Shimizu M, Sakai H, Shirakami Y, Yasuda Y, Kubota M, et al. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db Mice. Cancer Prevention Research. 2011; 4 (3): 396-403.
69. Wu D, Guo Z, Ren Z, Guo W, Meydani SN. Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radic Biol Med.2009; 47(5):636-43.
70. Kumar B, Gupta SK, Nag TC, Srivastava S, Saxena R. Green tea prevents hyperglycemia-induced retinal oxidative stress and inflammation in streptozotocin-induced diabetic rats. Ophthalmic Research. 2012; 47 (2): 103-8.
71. Shimada M, Mochizuki K, Sakurai N, Goda T. Dietary supplementation with epigallocatechin gallate elevates levels of circulating adiponectin in non-obese type-2 diabetic Goto-Kakizaki rats. Biosci Biotechnol Biochem. 2007; 71 (8): 2079-82.
72. Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2008; 27 (3): 363-70.
73. Derdemezis CS, Kiortsis DN, Tsimihodimos V, Petraki MP, Vezyraki P, et al. Effect of plant polyphenols on adipokine secretion from human SGBS adipocytes. Biochem Res Int. 2011; 2011. Article ID 285618. doi:10.115/2011/285618.
74. Gudbrandsen OA, Wergedahl H, Berge RK. A casein diet added isoflavone-enriched soy protein favorably affects biomarkers of steatohepatitis in obese Zucker rats. Nutr. 2009; 25 (5): 574-80.
75. Llaneza P, Gonzalez C, Fernandez-Inarrea J, Alonso A, Diaz F, et al. Soy isoflavones, diet and physical exercise modify serum cytokines in healthy obese postmenopausal women. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. 2011; 18 (4): 245-50.
76. Kobori M, Masumoto S, Akimoto Y, Oike H. Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice. Mol Nutr Food Res. 2011; 55 (4): 530-40.
77. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity. 2008; 16 (9): 2081-7.
78. Overman A, Chuang CC, McIntosh M. Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media. Int J Obes (Lond). 2011; 35 (9): 1165-72.
79. Boesch-Saadatmandi C, Wagner AE, Wolffram S, Rimbach G. Effect of quercetin on inflammatory gene expression in mice liver in vivo - role of redox factor 1, miRNA-122 and miRNA-125b. Pharmacol Res. 2012; 65 (5): 523-30.
80. Phung OJ, Baker WL, Matthews LJ, Lanosa M, Thorne A, Coleman CI. Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. Am J Clin Nutr. 2010; 91 (1): 73-81.
81. Hill AM, Coates AM, Buckley JD, Ross R, Thielecke F, Howe PR. Can EGCG reduce abdominal fat in obese subjects? J Am Coll Nutr. 2007; 26 (4): 396S-402S.
82. Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr. 2010; 29 (1): 31-40.
83. Knab AM, Shanely RA, Jin F, Austin MD, Sha W, Nieman DC. Quercetin with vitamin C and niacin does not affect body mass or composition. Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition et Metabolisme. 2011; 36(3):331-8.
84. Egert S, Rimbach G, Muller MJ. No evidence for a thermic effect of the dietary flavonol quercetin: a pilot study in healthy normal-weight women. Eur J Appl Physiol. 2011; 111 (5): 869-73.
85. Pfeuffer M, Auinger A, Bley U, Kraus-Stojanowic I, Laue C, et al. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammatory parameters in men with different APOE isoforms. NMCD. 2011; 23 November. doi:10.1016/j.numecd.2011.08.010. [Epub ahead of print]
86. Allison DB, Gadbury G, Schwartz LG, Murugesan R, Kraker JL, et al. A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. Eur J Clin Nutr. 2003; 57 (4): 514-22.
87. Deibert P, Konig D, Schmidt-Trucksaess A, Zaenker KS, Frey I, et al. Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soy-protein diet. Int J Obes Relat Metab Disord. 2004; 28 (10): 1349-52.
88. Hursel R, Westerterp-Plantenga MS. Green tea catechin plus caffeine supplementation to a high-protein diet has no additional effect on body weight maintenance after weight loss. Am J Clin Nutr. 2009; 89 (3): 822-30.
89. Campbell WW, Trappe TA, Wolfe RR, Evans WJ. The recommended dietary allowance for protein may not be adequate for older people to maintain skeletal muscle. J Gerontol A Biol Sci Med Sci. 2001; 56 (6): M373-80.
90. Morse MH, Haub MD, Evans WJ, Campbell WW. Protein requirement of elderly women: nitrogen balance responses to three levels of protein intake. J Gerontol A Biol Sci Med Sci. 2001; 56 (11): M724-30.
91. Holmes E, Li JV, Athanasiou T, Ashrafian H, Nicholson JK. Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. Trends Microbiol. 2011; 19 (7): 349-59.
92. Mestdagh R, Dumas ME, Rezzi S, Kochhar S, Holmes E, et al. Gut microbiota modulate the metabolism of brown adipose tissue in mice. J Proteome Res. 2012; 11 (2): 620-30.
93. van Duynhoven J, Vaughan EE, Jacobs DM, Kemperman RA, van Velzen EJ, et al. Metabolic fate of polyphenols in the human superorganism. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108 (SUPPL. 1.): 4531-8.
94. Del Rio D, Costa LG, Lean ME, Crozier A. Polyphenols and health: what compounds are involved? Nutrition, metabolism, and cardiovascular diseases. NMCD. 2010; 20 (1): 1-6.
95. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol. 2009; 65 (4): 331-41.
96. Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, et al. Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prevention Res. 2012; 5 (2): 309-19.